Can You Start Wegovy at a Higher Dose Than 0.25mg?

You've just been prescribed Wegovy and the 0.25mg pen feels frustratingly small

It's one of the most common things people say after their first prescription: the dose seems tiny, they feel no difference in appetite, and they wonder whether starting higher would accelerate results. That feeling is understandable. But the 0.25mg first step was specifically designed for your system, not for weight loss. Its job is to let your body acclimatise to semaglutide before the doses that actually suppress appetite arrive.

Semaglutide slows gastric emptying and acts on GLP-1 receptors in the brain to reduce hunger signals. Both effects become more pronounced as the dose rises, which is exactly why jumping straight to 1mg or 2.4mg without the lead-in period causes significantly more nausea, vomiting, and gastrointestinal discomfort than the gradual approach does. The titration schedule, as published in the Wegovy Summary of Product Characteristics on the eMC, reflects how the medicine was studied and approved; it isn't a cautious default that can be safely overridden.

If you want to understand what each step of the schedule involves, the Wegovy dose guide walks through the clinical reasoning behind each increment. The short version: at 0.25mg you're building tolerance. At 1.7mg and 2.4mg you're at the doses where the trial evidence for meaningful weight loss was generated.

Can a prescriber ever move someone faster through the schedule?

Occasionally, yes, but only under careful clinical judgement, and never at the patient's request alone. Someone transferring from a course of Ozempic (semaglutide for type 2 diabetes) who is already established on a given semaglutide dose, for instance, has a different starting point to someone who has never taken the medicine. Similarly, if a patient had a previous Wegovy course and is restarting after a short break, a prescriber may assess whether beginning again at 0.25mg is necessary or whether a higher re-entry point is clinically appropriate.

These are not decisions made by the patient. They follow clinical assessment, a review of tolerance history, and the prescriber's professional judgement. The question of starting semaglutide at a higher dose gets a longer answer in our dedicated guide, but the principle holds: any deviation from the standard schedule is a clinical decision, not a lifestyle one.

For people who are genuinely curious about the 1mg dose specifically, there are situations where staying at that level is assessed rather than escalating further. Our guide to staying on 1mg Wegovy covers when that might come up. Separately, the question of starting directly at 1mg is one our prescribers field regularly and is addressed there in detail.

The newer 7.2mg dose, does that change anything about starting higher?

In January 2026 the MHRA approved a 7.2mg maintenance dose of semaglutide (Wegovy), and on 14 April 2026 approved a dedicated single-dose 7.2mg pen, making it the highest approved dose of any GLP-1 medicine for weight management currently licensed in the UK. Trial data for this dose reported around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide results. It's covered in detail on our page on the 7.2mg Wegovy approval.

Crucially, however, 7.2mg is the maximum maintenance dose, it does not alter the starting dose. The titration still begins at 0.25mg and progresses through the same steps; the ladder simply now has an additional top rung. The MHRA's licence for this higher dose also specifies it is for adults with a BMI of 30 or above only, and it is not approved for the separate cardiovascular indication. Whether a specific dose or pen format is available is confirmed at consultation, stock and clinical suitability are assessed together. The wegovy higher-dose page explains the evidence and eligibility in full.

On the cost side, reaching a higher maintenance dose does affect monthly pricing. A transparent breakdown of what's included in private treatment costs is on our weight-loss treatments overview, worth reading before starting any dose conversation.

Side effects, storage, and what to do at each stage

One practical reason the titration schedule matters: side effects are dose-dependent. The NHS semaglutide medicines page lists nausea, vomiting, diarrhoea, constipation, and indigestion as the most commonly reported effects, noting they tend to be most noticeable when starting or after a dose increase. Skipping the lower doses and arriving at 2.4mg without the adjustment period concentrates that discomfort into a single phase rather than spreading and reducing it across the schedule.

A practical note: Wegovy pens are refrigerated medicines, stored at 2–8°C. Many people keep the current pen in the fridge door so it's easy to grab each week. If you ever travel or need to store a pen outside the fridge, the exact permitted window is in the Patient Information Leaflet, always check there rather than relying on general advice. Never freeze the pen.

If you're experiencing side effects you find difficult to manage at any point in the titration, the right conversation is with your prescriber, not a reason to drop back to a lower dose without guidance. Our general FAQs cover common questions at each stage, and our team is available through aftercare support seven days a week. Any concerns about severe or persistent symptoms should go to a clinician promptly.